Evolent Health, Inc. (EVH)
2025-06-30 | 2024-09-30 | 2024-06-30 | ||
|---|---|---|---|---|
| Revenue | 444,328 | 621,401 | 647,145 | |
| Selling, general and administrative expenses | 75,209 | 67,060 | 69,185 | |
| Loss on lease termination | - | - | - | |
| Depreciation and amortization expenses | 23,141 | 29,701 | 29,870 | |
| Cost of revenue | 343,943 | 540,708 | 540,302 | |
| Change in fair value of contingent consideration | 3,206 | 200 | - | |
| Total operating expenses | 445,499 | 637,669 | 639,357 | |
| Operating income (loss) | -1,171 | -16,268 | 7,788 | |
| Interest income | 1,084 | 794 | 1,370 | |
| Interest expense | 11,601 | 6,010 | 5,995 | |
| Gain (loss) from equity method investees | 197 | -2,229 | -1,700 | |
| Loss on option exercise | -196 | - | - | |
| Extinguishment of series a preferred stock | 9,000 | - | - | |
| Change in tax receivables agreement liability | - | - | - | |
| Other expense, net | -35 | -43 | -105 | |
| Income (loss) before income taxes | -20,722 | -23,756 | 1,358 | |
| Provision for (benefit from) income taxes | -825 | -619 | -238 | |
| Income (loss) before preferred dividends and accretion of series a preferred stock | -19,897 | -23,137 | 1,596 | |
| Dividends and accretion of series a preferred stock | 31,193 | 8,094 | 7,979 | |
| Net loss attributable to common shareholders of evolent health, inc. - diluted | -51,090 | -31,231 | -6,383 | |
| Basic (in dollars per share) | -0.44 | -0.27 | -0.06 | |
| Basic (in shares) | 115,882,000 | 114,862,000 | 114,688,000 | |
| Diluted (in dollars per share) | -0.44 | -0.27 | -0.06 | |
| Diluted (in shares) | 115,882,000 | 114,862,000 | 114,688,000 | |